Status:
COMPLETED
Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation
Lead Sponsor:
Bayer
Collaborating Sponsors:
Janssen Research & Development, LLC
Conditions:
Atrial Fibrillation
Eligibility:
All Genders
19+ years
Brief Summary
The purpose of the study is to collect additional information of Xarelto treatment in routine clinical practice. Patients affected by atrial fibrillation and who will get Xarelto as a prophylactic tre...
Detailed Description
The study takes place in Korea and Taiwan. Approximately a total of 1200 patients will be included in the study within 12 months. The observation period for each patient is 1 year from enrollment into...
Eligibility Criteria
Inclusion
- Female and male patients aged 19 years or older (Korea) and aged 20 years or older (Taiwan)
- Diagnosis of NVAF
- Patients for whom the decision to initiate treatment with rivaroxaban is made as per physician's routine treatment practice
- Treatment naïve regarding stroke prevention for atrial fibrillation
- Signed informed consent
Exclusion
- Contraindications for rivaroxaban according to the local market authorization/summary of product characteristics (SmPC)
- Patients participating in an investigational program with interventions outside of routine clinical practice
Key Trial Info
Start Date :
September 11 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 20 2019
Estimated Enrollment :
1216 Patients enrolled
Trial Details
Trial ID
NCT03284762
Start Date
September 11 2017
End Date
November 20 2019
Last Update
November 24 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Different facilities
Multiple Locations, South Korea
2
Different facilities
Multiple Locations, Taiwan